$ASXC Question for serious longs very familiar with this company. I owned this stock last year and sold it. I am looking at its current price sitting under $3 and Ladenburg analyst Jeffrey Cohen downgraded to Neutral from Buy without a price target and then you have H.C. Wainwright analyst Swayampakula Ramakanth coverage of a Buy rating and $4 price target. "The company is digitizing laparoscopy with its lead product, Senhance, Ramakanth tells investors in a research note. With roughly 16M global laparoscopic procedures performed annually, Asensus has a "significant market opportunity," says the analyst. He projects its total revenue to reach $697M in 2030 from $6M in 2021." Is this guy serious with $697 Million? That is insane. Read more at: thefly.com/landingPageNews.... Read more at: thefly.com/landingPageNews....
5
2
2 Likes